Key Study Personnel:
Hong Tao, PhD, RN - Principal Investigator
Gina McBride, RN - Coordinator
Patricia Robinson, PhD, ARNP - Sub-Investigator
Pamela J. Jennelle, MS - Coordinator
Ashley Kohrt, BS - Lead Coordinator
David Richard, PhD - Independent Consultant
Number of Participants:
- Phase 1: 620
- Phase 2: 620
Participants who meet the following inclusion criteria are recruited from the inpatient setting at AdventHealth Orlando:
- Primary or secondary admission diagnosis of heart failure, chronic obstructive pulmonary disease, acute myocardial infraction, coronary artery bypass graft, pneumonia, total knee or hip replacement, or stroke.
- Age 21 and over
- Able to provide informed consent
- Able to speak and read English
- Able to complete and electronic survey or relay answers to questions to another party who may complete the survey for the participant
- Resides in Central Florida and anticipates continued residence in Central Florida for the next 120 days
- Planned discharge to a non-hospital or residential care environment
- Under age 21
- Does not speak or read English
- Permanent residence is outside Central Florida
- Not of cognitive capacity to provide valid responses
- Dementia or cognitive impairment that renders subject unable to provide informed consent
- Prescribed a known psychoactive medication that might reasonably affect the ability of the participants to provide valid responses
Patients who have given informed consent are asked to complete an 82-question assessment including questions about their mental, physical, and spiritual well-being. The participant’s medical record will be reviewed for instances of readmission up to 120 days post- discharge. Demographic and health information will also be collected from the medical record.
Phase 1 comprises initial item development and measurement validation of a new tool for identifying hospitalized patients at high risk for preventable readmission. Primary tasks include item construction and content validation, data collection, analysis, and instrument refinement.
Phase 2 involves administering the refined, condensed instrument to a new group of patients to determine final item content for the instrument, its factor structure, and its predictive validity.
Phase 1: Completed January 2018
Phase 2: Scheduled May 2018
Targeted Completion Date:
Questions about study:
Contact: Dr. Patricia Robinson